Highlights
FUTURA MEDICAL Annual Report 08 01
Substantial progress across the Company with receipt of positive regulatory
opinion relating to the pharmaceutical aspects of CSD500, which will be the first
commercial product
TPR100 Positive results from phase I study with commercial negotiations
ongoing
PET500 Positive results from phase I study
RAD100 New product for local anaesthesia prior to injections which has shown
impressive results in early clinical work
Net loss of £1.93 million (2007: net loss of £2.25 million)
Cash of £0.78 million at 31 December 2008 with a further £1.00 million equity
funding raised in March 2009
Company Overview
1 Highlights
2 Futura at a Glance
3 Product Pipeline
4 Chairmans and Chief Executives Joint Review
9 Directors Report: Financial Review
12 Directors Report: Business Review
16 Directors Report: Corporate Governance
21 Directors Report: Remuneration Report
26 Directors Report: Statement of Responsibilities
27 Independent Auditors Report
28 Consolidated Income Statement
29 Consolidated Statement of Changes in Equity
30 Consolidated Balance Sheet
31 Consolidated Cash Flow Statement
32 Notes to the Consolidated Financial Statements
48 Parent Company Balance Sheet
49 Notes to the Parent Company Financial Statements
51 Company Information
Contents
